Vanguard Global Advisers’s Capricor Therapeutics CAPR Stock Holding History
Bought
Maintained
Sold
Other funds holding CAPR
Vanguard Global Advisers's CAPR Position: Q3 2026 in Review
Vanguard Global Advisers reduced its Capricor Therapeutics (CAPR) stake by 30% in Q3 2026, selling an estimated $95.2K and leaving 19,952 shares worth $189K. The position accounts for ﹤0.01% of the portfolio, ranked #2506.
Vanguard Global Advisers first reported a position in CAPR in Q1 2026 and has held it in 3 quarters since. The position peaked at $741K in Q1 2026. 158 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.
- Vanguard Global Advisers held 19,952 shares of Capricor Therapeutics worth $189K as of Q3 2026.
- Vanguard Global Advisers sold 8,600 Capricor Therapeutics shares in Q3 2026, an estimated $95.2K.
- Capricor Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2506 holding.
- Vanguard Global Advisers first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Capricor Therapeutics position peaked at $741K in Q1 2026.
- 158 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.